Intellia Therapeutics Inc Stock News

Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline tar

Teladoc Health is roaring ahead on the path to profitability, making gains in EBITDA and free cash flow. One of Intellia Therapeutics' gene-editing candidates is entering late-stage studies, a step cl

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for i

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Intellia Therapeutics, Inc. enrollment completion for the phase 2 study using NTLA-2002 for the treatment of hereditary angioedema is expected in Q4 2023; Results expected in 2024. Pending positive fe

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President an

The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.

Intellia will soon start a phase 3 gene-editing trial, the first of its kind. Succeeding with the trial will not be the last hurdle it needs to overcome.

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l

Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.

Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.

Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.